Land: Armenien
Sprog: engelsk
Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
betamethasone (betamethasone valerate), neomycin (neomycin sulphate)
Medpharma Pharm. & Chem. Inds LLC
D07CC01
betamethasone (betamethasone valerate), neomycin (neomycin sulphate)
0,1%+ 0,5%
ointment
30g aluminium tube
Prescription
Registered
2015-12-02
BETAMED-N ® CREAM BETAMED-N ® OINTMENT TOPICAL CORTICOSTEROID WITH ANTIMICROBIAL (BETAMETHASONE VALERATE & NEOMYCIN SULPHATE) PHARMACEUTICAL PRESENTATIONS: BETAMED-N CREAM BETAMED-N OINTMENT COMPOSITION: BETAMED-N CREAM: Betamethasone 0.1% w/w (as Betamethasone Valerate) and Neomycin Sulphate 0.5% w/w. IN-ACTIVE INGREDIENTS: Cetostearyl alcohol, Cetomacrogol 1000, Methyl paraben, Propyl paraben, Liquid paraffin, Monobasic sodium phosphate dihydrate, White soft paraffin and Purified water BETAMED-N OINTMENT: Betamethasone 0.1% w/w (as Betamethasone Valerate) and Neomycin Sulphate 0.5% w/w. IN-ACTIVE INGREDIENTS: Cetostearyl alcohol, Cetomacrogol 1000, Liquid paraffin and White soft paraffin PROPERTIES: BETAMED-N_ _ is a combination therapy of Betamethasone which is a medium glucocorticoid used in moderate inflammatory diseases and eczematous dermatosis and Neomycin Sulphate which is an aminoglycoside antibiotic that has a bactericidal action against many gram-negative aerobes and against some strains of staphylococci. Neomycin Sulphate used topically in the treatment of infections of the skin due to susceptible microorganisms. INDICATIONS: Eczema, including atopic, infantile and discoid eczema; psoriasis; neurodermatoses, seborrheic dermatitis; contact sensitivity reactions and insect bites when infection is present or suspected. CONTRA – INDICATIONS: The product is contra-indicated in case of: Rosacea, acne and perioral dermatitis, primary cutaneous viral reactions e.g. Herpes simplex, chicken pox, hypersensitivity to any of its components. The use of Betamed-N is not indicated in the treatment of primarily infected skin lesions caused by infections with fungi e.g. candidiasis, tinea. Primary or secondary infections due to yeast, peri-anal and genital pruritus, dermatoses in children under 1 year of age including dermatitis and napkin eruptions. WARNINGS AND PRECAUTIONS: - Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression, with Læs hele dokumentet
Mt[PHRRMR Pharma. & Chem. Ind's L.L.C. Industrial Area 13 - Sharjah U.A.E. 7- MtIPHRRMfl Product Name: Betamed-N Ointment Company Name: Medpharma Pharm. & Chem.Ind.'s LLC Strength: Betamethasone O.lo/o flw as Betamethasone 1 7-Valerate, Neomycin sulphate 0.5o/o wlw Pack size: 30 gm SUMMARY OF PRODUCT CHARACTERISTICS BETAMED.N OINTMENT (Pack Size Sogmf ,uru#r'*'#o$i*u,0, *tu. *L€ \ .Yry"#m,"a,ttts V .qEFF -! MT[PHRRMR Pharma. & Chem. Ind's L.L.C. Industrial Area 13 - Shariah U.A.E. C'L Betamed-N Ointment Company Name: Medpharma Pharm. & LLC Chem.Ind.'s 30 gm 'U,J U MtIPHRHMR Product Name: Betamethasone 0.17o ilw as 7 Betamethasone L7-Valerate, '{ Packstze: Neomvein sulnhate 0.5o/" wlw BETAMED-N OINTMENT 30gm L.3.L Summary of Product Characteristics (SPC) 1. Name of the Medicinal Product Betamed-N Ointment 2. Qualitative and Quantitative Composition 0.1% w/w Betamethasone as the valerate ester and 0.5ohwlw Neomycin sulphate in ointment base. 3. Pharmaceutical Form Ointment 4. Clinical Data 4.1 Therapeutic Indications Eczema, including atopic, infantile and discoid eczema; psoriasis; neurodermatoses; seborrheic dermatitis; contact sensitivity reactions; insect bites when infection is present or suspected. 4.2 Posology and Method of Administration: For topical administration. Betamed-N Ointment for dry lichenified or scal-v lesions, but this is not invariably so. In adults, in the more resistant lesions, such as the thickened plaques of psoriasis on elbows and knees, the effects of Betamed-N can be enhanced, if necessary. by occluding the treatment area with polS.thene film. Ove:rnight occlusion only is usuall-v adequate to bring about a satisfactory response in such lesions, thereafter improvement can usually be maintained by regular application without occlusion. Treatment should not be continued for more than 7 days without rnedical supen ision. Adults and children aged 2 years and over: A small quantity should be applied to the al{bcted area two or three times dail,v until improvement occurs. lt may then be pos Læs hele dokumentet